Related Experiment Videos
Somatostatin impairs sleep in elderly human subjects
R M Frieboes1, H Murck, T Schier
1Department of Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Summary
Somatostatin (SRIF) administration worsens sleep quality in elderly individuals by reducing total sleep time and REM sleep. This peptide may impact older adults more due to age-related changes in the growth hormone (GH) axis.
Area of Science:
- Neuroscience
- Endocrinology
- Sleep Medicine
Background:
- Sleep quality declines with age, becoming more fragmented.
- Growth hormone (GH) release, linked to sleep, decreases in older adults.
- GH secretion is balanced by GH-releasing hormone (GHRH) and somatostatin (SRIF).
Purpose of the Study:
- To investigate the effects of somatostatin (SRIF) on sleep electroencephalogram (EEG) in elderly individuals.
- To determine if SRIF influences sleep architecture in aging populations.
Main Methods:
- Elderly participants (60-73 years) received 50 micrograms of SRIF-14 hourly from 2200 to 0100.
- Sleep EEG was monitored to assess sleep stages and duration.
- Compared sleep patterns before and after SRIF administration.
Main Results:
- SRIF administration led to a significant decrease in total sleep time.
- Rapid eye movement (REM) sleep duration was significantly reduced post-SRIF.
- Increased time spent awake during the initial sleep cycle was observed.
Conclusions:
- Peripheral SRIF administration appears to deteriorate sleep quality in the elderly.
- Age-related decline in the GHRH-GH axis may enhance SRIF's effect on sleep.
- Increased blood-brain barrier permeability in the elderly might contribute to SRIF's heightened impact on sleep EEG.